OSE Immunotherapeutics Announces Positive Results from Phase 1 Clinical Study of Anti-IL-7 Receptor Antagonist OSE-127

NEXT STORY
Aslan Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
PREV STORY
Mateon Therapeutics Team Publishes Three New Peer-Reviewed Oncology Articles Outlining the Clinical Impact Potential of Its First-In-Class Anti-TGF-Beta RNA Therapeutic OT101/Trabedersen
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

10x Genomics Becomes First One Medical Customer to Deploy Cohort-Based COVID-19 Employee Testing 

author_avatar
NASDAQ Market News

Applied Therapeutics Reports Second Quarter 2020 Financial Results

author_avatar
NASDAQ Market News

Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors

author_avatar
NASDAQ Market News